GICS Sector : Healthcare
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix reported a net loss of €68.1 million for the full year 2024, marking a 72% increase from the previous year, primarily due to a one-time non-cash liability recognition related to the transfer of NANORAY-312 sponsorship to Johnson & Johnson (JNJ). This resulted in negative revenue of €7.2 million, a significant deviation from typical reporting standards. Despite this, the company maintained a robust cash position of €49.7 million at year-end, supported by a $20 million milestone payment and an amended collaboration agreement with JNJ, which extended its cash runway into mid-2026.
Publication Date: May -04
Nanobiotix demonstrated substantial progress in its pipeline, particularly through its partnership with JNJ. The collaboration on NBTXR3, now known as JNJ-1900, targets a potential $10 billion market in lung and head and neck cancer, as highlighted by CEO Laurent Levy. The company is advancing multiple clinical trials, including the pivotal Phase 3 NANORAY-312 study in head and neck cancer and the randomized Phase 2 CONVERGE study in Stage III lung cancer, both under JNJ's responsibility for costs and timelines. Additionally, promising results in pancreatic cancer and early-stage studies in recurrent metastatic head and neck cancer and non-small cell lung cancer underscore the versatility of Nanobiotix's pipeline.
Despite the negative P/E and P/B ratios, reflecting the company's current loss-making status and high-risk profile, Nanobiotix's P/S ratio of 3.4 suggests a reasonable valuation relative to its peers. The EV/EBITDA of -4.5 indicates significant leverage, but the company's extended cash runway provides breathing room for pipeline advancement. With multiple clinical data readouts expected in 2024, including results from the 1100 trial and Phase 1 esophageal cancer study, the stock's upside potential hinges on successful trial outcomes and further validation of the Curadigm platform.
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Nov -24
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Nov -24
Soft Tissue Sarcoma Market Analysis Report 2025-2035, Profiles of Novartis, Nanobiotix, Adaptimmune, and Ipsen Pharma
Nov -19
Voting Rights and Shares Capital of the Company
Nov -14
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Nov -13
Nanobiotix (ENXTPA:NANO): Evaluating Valuation After $71 Million Royalty Deal Expands Growth Prospects
Nov -13
Why Nanobiotix (ENXTPA:NANO) Is Up 5.9% After Securing $71M in Non-Dilutive Financing and What’s Next
Nov -13
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Nov -11
Nanotherapeutics from Nanobiotix S.A. growth driven by increasing adoption in cancer treatment, rising demand for targeted therapies, and advancements in nanotechnology. Strong pipeline of products, strategic partnerships, and expanding global presence also contribute to 15% growth.
A novel, first-in-class radioenhancer designed to increase the efficacy of radiotherapy in various types of cancer
A combination therapy of NBTXR3 with anti-PD-1 checkpoint inhibitor to enhance the immune response in cancer treatment
A platform technology using nanoparticles to deliver chemotherapy directly to cancer cells
A treatment approach using NBTXR3 to enhance the effects of local radiation therapy in cancer treatment
Nanobiotix S.A. operates in the biotechnology industry, where substitutes are limited. However, the company's focus on developing novel cancer treatments may lead to some substitution risks.
Nanobiotix S.A.'s customers are primarily pharmaceutical companies and research institutions, which have limited bargaining power due to the company's specialized products and services.
Nanobiotix S.A. relies on a few key suppliers for raw materials and equipment, which may lead to some bargaining power. However, the company's strong relationships with suppliers mitigate this risk.
The biotechnology industry is highly competitive, and new entrants may pose a significant threat to Nanobiotix S.A.'s market share and intellectual property.
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Nanobiotix S.A. faces intense rivalry from companies with similar products and services.
| Value | |
|---|---|
| Debt Weight | 104.11% |
| Debt Cost | 10.21% |
| Equity Weight | -4.11% |
| Equity Cost | 10.21% |
| WACC | 10.21% |
| Leverage | -2532.94% |
Value: 7.6
Growth: 7.4
Quality: 2.4
Yield: 0.0
Momentum: 6.0
Volatility: 10.0
1-Year Total Return ->
Value: 10.0
Growth: 3.1
Quality: 8.8
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.4
Growth: 9.0
Quality: 7.4
Yield: 0.0
Momentum: 6.0
Volatility: 2.0
1-Year Total Return ->
Value: 6.0
Growth: 7.0
Quality: 5.9
Yield: 0.0
Momentum: 9.5
Volatility: 1.3
1-Year Total Return ->
Value: 8.0
Growth: 2.9
Quality: 5.0
Yield: 0.0
Momentum: 3.0
Volatility: 4.7
1-Year Total Return ->
Value: 4.0
Growth: 6.9
Quality: 4.1
Yield: 0.0
Momentum: 7.0
Volatility: 0.3
1-Year Total Return ->